PYXS Quote, Financials, Valuation and Earnings

HOOKIPA Pharma has a net margin of -20.17% compared to Pyxis Oncology's net margin of -294.3%. Pyxis Oncology's return on equity of -- beat HOOKIPA Pharma's return on equity of -48.48%.

Pyxis Oncology has a consensus price target of $8.83, signalling upside risk potential of 477.34%. On the other hand HOOKIPA Pharma has an analysts' consensus of $16.33 which suggests that it could grow by 817.6%. Given that HOOKIPA Pharma has higher upside potential than Pyxis Oncology, analysts believe HOOKIPA Pharma is more attractive than Pyxis Oncology.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HOOKIPA Pharma has a beta of 0.713, suggesting its less volatile than the S&P 500 by 28.74%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HOOKIPA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. HOOKIPA Pharma pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are larger than HOOKIPA Pharma quarterly revenues of $4.7M. Pyxis Oncology's net income of -$21.2M is lower than HOOKIPA Pharma's net income of -$13.8M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while HOOKIPA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 0.44x for HOOKIPA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -20.17% compared to Pyxis Oncology's net margin of 18.95%. Pyxis Oncology's return on equity of -- beat Merck &'s return on equity of 29.26%.

Pyxis Oncology has a consensus price target of $8.83, signalling upside risk potential of 477.34%. On the other hand Merck & has an analysts' consensus of $127.05 which suggests that it could grow by 25.81%. Given that Pyxis Oncology has higher upside potential than Merck &, analysts believe Pyxis Oncology is more attractive than Merck &.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.09% to investors and pays a quarterly dividend of $0.81 per share. Pyxis Oncology pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are smaller than Merck & quarterly revenues of $16.7B. Pyxis Oncology's net income of -$21.2M is lower than Merck &'s net income of $3.2B. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Merck &'s PE ratio is 21.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 4.06x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -20.17% compared to Pyxis Oncology's net margin of -49.65%. Pyxis Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Pyxis Oncology has a consensus price target of $8.83, signalling upside risk potential of 477.34%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 393.38%. Given that Pyxis Oncology has higher upside potential than NovaBay Pharmaceuticals, analysts believe Pyxis Oncology is more attractive than NovaBay Pharmaceuticals.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pyxis Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Pyxis Oncology's net income of -$21.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Pyxis Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -20.17% compared to Pyxis Oncology's net margin of 25.23%. Pyxis Oncology's return on equity of -- beat Pfizer's return on equity of 4.63%.

Pyxis Oncology has a consensus price target of $8.83, signalling upside risk potential of 477.34%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.57%. Given that Pyxis Oncology has higher upside potential than Pfizer, analysts believe Pyxis Oncology is more attractive than Pfizer.

Pyxis Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Pyxis Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.27% to investors and pays a quarterly dividend of $0.42 per share. Pyxis Oncology pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Pyxis Oncology quarterly revenues are $16.1M, which are smaller than Pfizer quarterly revenues of $17.7B. Pyxis Oncology's net income of -$21.2M is lower than Pfizer's net income of $4.5B. Notably, Pyxis Oncology's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pyxis Oncology is -- versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.